Endo International plc – Ordinary Shares (NASDAQ:ENDP) announced today that Suketu Upadhyay, Executive Vice President and Chief Financial Officer, is leaving the Company effective November 22, 2016 to assume a senior-level finance position at a global biopharmaceutical company. Blaise Coleman, Endo’s Senior Vice President of Global Finance Operations, will serve as Interim Chief Financial Officer. The Company will promptly begin a search for a permanent Chief Financial Officer.
“We would like to thank Suky for his dedicated service to Endo, his role in transforming the Company and in building a strong Finance organization. We wish him the very best in his professional endeavors and much continued success,” said Paul Campanelli, President and Chief Executive Officer of Endo. “We recently reaffirmed Endo’s third quarter and full year 2016 financial guidance and we remain confident in our 2016 performance. I look forward to working with Suky through his transition and closely with Blaise as we complete a product-by-product assessment of our portfolio and further sharpen Endo’s strategy and operational focus.”
“My time at Endo has been pivotal for my career and I am very proud of the best-in-class teams I have built and led for the Company while contributing to the transformation of Endo since 2013,” said Mr. Upadhyay. “I want to thank Paul for the past year of collaboration and for the confidence he and the Board have put in my abilities. I am confident that Paul’s and the leadership team’s focus on execution will drive success for the Company into the future.” (Original Source)
Shares of Endo are down nearly 3% to $20 in after-hours trading Thursday. ENDP has a 1-year high of $68.84 and a 1-year low of $12.56. The stock’s 50-day moving average is $20.59 and its 200-day moving average is $20.23.
On the ratings front, Endo has been the subject of a number of recent research reports. In a report issued on October 14, Guggenheim analyst Louise Chen reiterated a Buy rating on ENDP, with a price target of $35, which implies an upside of 77% from current levels. Separately, on September 29, Northland Securities’ David Buck upgraded the stock to Buy and has a price target of $27.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Louise Chen and David Buck have a total average return of -11.0% and 22.4% respectively. Chen has a success rate of 40% and is ranked #4000 out of 4180 analysts, while Buck has a success rate of 69% and is ranked #365.
Overall, 5 research analysts have assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $26.00 which is 31% above where the stock opened today.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets.